胃胃肠道间质瘤。是否有必要在中等风险人群中使用伊马替尼?

IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Hippokratia Pub Date : 2021-07-01
O Yalav, S Gumus, M O Gul, I C Eray, A Rencuzogullari
{"title":"胃胃肠道间质瘤。是否有必要在中等风险人群中使用伊马替尼?","authors":"O Yalav,&nbsp;S Gumus,&nbsp;M O Gul,&nbsp;I C Eray,&nbsp;A Rencuzogullari","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A gastrointestinal stromal tumor (GIST) is a tumor that occurs in the gastrointestinal tract, most frequently in the stomach or small intestine. This study aimed to reveal the clinical, histopathological, and immunohistochemical features of patients with GIST and to determine the effect of adjuvant tyrosine kinase inhibitor (TKI) use on survival rates in intermediate-risk gastric GIST cases.</p><p><strong>Methods: </strong>Clinical characteristics, histopathological findings, and oncological outcomes of 51 patients operated on for gastric GIST between 2010 and 2019 were analyzed retrospectively. Patients treated with neoadjuvant and adjuvant TKI were identified. The effect of adjuvant therapy on survival in the intermediate-risk group was examined.</p><p><strong>Results: </strong>There were 33 females and 18 males, with a mean age of 64.9 ± 12.8 years. The most common surgical procedure was gastric wedge resection. Three cases were treated with laparoscopy, and 48 underwent open surgery. A multi-visceral resection was carried out in three cases. All cases underwent R0 resection. In the intermediate-risk group, there were no statistical differences between individuals receiving adjuvant therapy (n =12) and those not receiving adjuvant therapy (n =6) regarding survival rates (p =0.157). The average follow-up period was 54.9 (min: 2 - max: 106) months. Over this period, in three and five patients, recurrence and metastases occurred, respectively, and seven patients succumbed to the disease. Disease-free survival for five years was 93.7 %, metastasis-free survival was 83.4 %, and overall survival was 86.7 %. HIPPOKRATIA 2021, 25 (3):113-118.</p><p><strong>Conclusions: </strong>This study showed that adjuvant TKI therapy did not affect survival rates in intermediate-risk gastric GIST.</p>","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"25 3","pages":"113-118"},"PeriodicalIF":0.3000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851140/pdf/hippokratia-25-113.pdf","citationCount":"0","resultStr":"{\"title\":\"Gastric gastrointestinal stromal tumors. Is there a necessity to use imatinib in the intermediate-risk group?\",\"authors\":\"O Yalav,&nbsp;S Gumus,&nbsp;M O Gul,&nbsp;I C Eray,&nbsp;A Rencuzogullari\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A gastrointestinal stromal tumor (GIST) is a tumor that occurs in the gastrointestinal tract, most frequently in the stomach or small intestine. This study aimed to reveal the clinical, histopathological, and immunohistochemical features of patients with GIST and to determine the effect of adjuvant tyrosine kinase inhibitor (TKI) use on survival rates in intermediate-risk gastric GIST cases.</p><p><strong>Methods: </strong>Clinical characteristics, histopathological findings, and oncological outcomes of 51 patients operated on for gastric GIST between 2010 and 2019 were analyzed retrospectively. Patients treated with neoadjuvant and adjuvant TKI were identified. The effect of adjuvant therapy on survival in the intermediate-risk group was examined.</p><p><strong>Results: </strong>There were 33 females and 18 males, with a mean age of 64.9 ± 12.8 years. The most common surgical procedure was gastric wedge resection. Three cases were treated with laparoscopy, and 48 underwent open surgery. A multi-visceral resection was carried out in three cases. All cases underwent R0 resection. In the intermediate-risk group, there were no statistical differences between individuals receiving adjuvant therapy (n =12) and those not receiving adjuvant therapy (n =6) regarding survival rates (p =0.157). The average follow-up period was 54.9 (min: 2 - max: 106) months. Over this period, in three and five patients, recurrence and metastases occurred, respectively, and seven patients succumbed to the disease. Disease-free survival for five years was 93.7 %, metastasis-free survival was 83.4 %, and overall survival was 86.7 %. HIPPOKRATIA 2021, 25 (3):113-118.</p><p><strong>Conclusions: </strong>This study showed that adjuvant TKI therapy did not affect survival rates in intermediate-risk gastric GIST.</p>\",\"PeriodicalId\":50405,\"journal\":{\"name\":\"Hippokratia\",\"volume\":\"25 3\",\"pages\":\"113-118\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851140/pdf/hippokratia-25-113.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hippokratia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:胃肠道间质瘤(GIST)是一种发生在胃肠道的肿瘤,最常见于胃或小肠。本研究旨在揭示GIST患者的临床、组织病理学和免疫组织化学特征,并确定辅助酪氨酸激酶抑制剂(TKI)对中危胃GIST患者生存率的影响。方法:回顾性分析2010年至2019年间51例胃GIST手术患者的临床特征、组织病理学表现和肿瘤学结果。确定了接受新辅助和辅助TKI治疗的患者。研究了辅助治疗对中危组生存率的影响。结果:女性33例,男性18例,平均年龄64.9±12.8岁。最常见的外科手术是胃楔形切除术。其中3例采用腹腔镜手术治疗,48例采用开放手术治疗。对3例患者进行了多脏器切除术。所有病例均行R0切除术。在中危组中,接受辅助治疗的个体(n=12)和未接受辅助治疗(n=6)的个体在生存率方面没有统计学差异(p=0.157)。平均随访期为54.9(最小:2-最大:106)个月。在此期间,三名和五名患者分别出现复发和转移,七名患者死于该疾病。五年无病生存率为93.7%,无转移生存率为83.4%,总生存率为86.7%。HIPPOKRATIA 2021,25(3):113-118结论:本研究表明,辅助TKI治疗不会影响中危胃GIST的生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Gastric gastrointestinal stromal tumors. Is there a necessity to use imatinib in the intermediate-risk group?

Gastric gastrointestinal stromal tumors. Is there a necessity to use imatinib in the intermediate-risk group?

Gastric gastrointestinal stromal tumors. Is there a necessity to use imatinib in the intermediate-risk group?

Background: A gastrointestinal stromal tumor (GIST) is a tumor that occurs in the gastrointestinal tract, most frequently in the stomach or small intestine. This study aimed to reveal the clinical, histopathological, and immunohistochemical features of patients with GIST and to determine the effect of adjuvant tyrosine kinase inhibitor (TKI) use on survival rates in intermediate-risk gastric GIST cases.

Methods: Clinical characteristics, histopathological findings, and oncological outcomes of 51 patients operated on for gastric GIST between 2010 and 2019 were analyzed retrospectively. Patients treated with neoadjuvant and adjuvant TKI were identified. The effect of adjuvant therapy on survival in the intermediate-risk group was examined.

Results: There were 33 females and 18 males, with a mean age of 64.9 ± 12.8 years. The most common surgical procedure was gastric wedge resection. Three cases were treated with laparoscopy, and 48 underwent open surgery. A multi-visceral resection was carried out in three cases. All cases underwent R0 resection. In the intermediate-risk group, there were no statistical differences between individuals receiving adjuvant therapy (n =12) and those not receiving adjuvant therapy (n =6) regarding survival rates (p =0.157). The average follow-up period was 54.9 (min: 2 - max: 106) months. Over this period, in three and five patients, recurrence and metastases occurred, respectively, and seven patients succumbed to the disease. Disease-free survival for five years was 93.7 %, metastasis-free survival was 83.4 %, and overall survival was 86.7 %. HIPPOKRATIA 2021, 25 (3):113-118.

Conclusions: This study showed that adjuvant TKI therapy did not affect survival rates in intermediate-risk gastric GIST.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hippokratia
Hippokratia MEDICINE, GENERAL & INTERNAL-
CiteScore
1.10
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process). Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信